Abstract
Introduction A large majority of genome-wide significant (GWS) loci identified for substance use traits (SUTs) in genome-wide association studies (GWAS) have been for alcohol and smoking-related phenotypes. GWAS of opioid use disorder (OUD) and cannabis use disorder (CUD) have lagged those of the two historically legal substances.
Methods We applied multi-trait analysis of GWAS (MTAG) to 2,888,727 single nucleotide polymorphisms (SNPs) common to GWAS of four SUTs (OUD, CUD, alcohol use disorder [AUD], and smoking initiation [SMK]) in European-ancestry (EUR) subjects. We calculated polygenic risk scores (PRS) for the four traits in an independent sample (i.e., the Yale-Penn sample; N=5,692 EUR) and examined the power increment for each set of MTAG-GWAS summary statistics relative to those of the input GWAS.
Results MTAG increased the effective sample size for all four SUTs, which showed high pairwise genetic correlations. After clumping, MTAG identified independent GWS SNPs for all 4 traits: 41 SNPs in 36 loci (including 5 novel loci not previously associated with any SUT) for OUD; 74 SNPs in 60 loci (including 4 novel loci) for CUD; 63 SNPs in 52 loci (including 10 novel loci) for AUD; and 183 SNPs in 144 loci (including 8 novel loci) for SMK. In PRS analyses in the Yale-Penn sample, the MTAG-derived PRS consistently yielded more significant associations with both the corresponding substance use disorder diagnosis and multiple related phenotypes than each of the 4 GWAS-derived PRS.
Conclusions MTAG boosted the number of GWS loci for the 4 SUTs, including identifying genes not previously linked to any SUT. MTAG-derived PRS also showed stronger associations with expected phenotypes than PRS for the input GWAS. MTAG can be used to identify novel associations for SUTs, especially those with sample sizes smaller than for historically legal substances.
Competing Interest Statement
Dr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. The other authors have no disclosures to make.
Funding Statement
Supported by the Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center, the Million Veteran Program (I01 BX004820 and I01 CX001734) and NIH grants P30 DA046345 (HRK), R01 AA026364 (JG), K01 AA028292 (RLK), T32 AA028259 (JDD), and K01DA051759 (ECJ).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Yale-Penn participants were recruited at 5 sites (Yale University School of Medicine (APT Foundation; New Haven, CT), the University of Connecticut Health Center (Farmington, CT), the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA), the Medical University of South Carolina (Charleston, SC), and McLean Hospital (Belmont, MA) in the United States for genetic studies of cocaine, opioid, and alcohol dependence. The study was approved by the institutional review board at each site and all participants gave written informed consent prior to data collection.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary statistics used in this work are publicly available.
